Jagsonpal Pharma appoints Anil Kumar Matai as Independent Director

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+7.6%1-day move

₹223.00

prior close

₹222.32

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.5+2.4+2.7—+7.6+6.5+5.3+6.6+6.7+2.6+0.0———

Up moveDown movePending

AI summary

Jagsonpal Pharmaceuticals has appointed Mr. Anil Kumar Matai (DIN: 03122685) as an Additional Director in the category of Non-Executive Independent Director, effective June 25, 2026, subject to shareholder approval. Mr. Matai brings over three decades of leadership experience in the pharmaceutical and healthcare sectors. The company, listed on NSE (JAGSNPHARM) and BSE (507789), has a 40+ year track record in gynaecology, orthopaedics, dermatology and child-care segments, with 20+ brands ranked in the top 5 in their molecule categories.

Likely market impact

Adds an experienced pharma veteran to the board, subject to shareholder approval. Generally a positive signal for corporate governance.